$21.8 Million Series C for Vital Liver Treatment

Vital Therapies, a San Diego,Nike Air VaporMax pas cher CA-based company developing a human cell-based artificial liver, has completed a $21.8 million Series C financing. The money will go toward continued development of the company’s ELAD (Extracorporeal Liver Assist Device) System, which augments the metabolic functions of a patient’s liver, thereby enabling a bridge to transplant or liver recovery.

elad-cartridge.jpgELAD consists of four cartridges (see left) containing cells that function like a normal human liver. The cells metabolize toxins and remove waste products while delivering essential proteins into the plasma. These Nike Air VaporMax pas cher cartridges are incorporated into a blood pumping system at the patient’s bedside and enable continuous treatment for up to 12 days. The key to ELAD’s performance is a proprietary human hepatocyte cell line that can be grown, stored and shipped worldwide.

Pivotal human trials at two hospitals in Beijing, China, have already shown ELAD to be a promising therapy for serious, acute liver failure. To date, only liver transplantation has been shown to increase survival. However, demand for liver transplantation far exceeds the supply of donor livers, creating a need for Nike Air VaporMax pas cher an alternative life saving therapy. In China alone, an estimated 160 million people suffer from chronic liver infections such as Hepatitis B and C.

In a statement announcing the financing — led by Versant Ventures which was joined by new investors Delphi Ventures, HBM BioMed China and DFJ DragonFund China — Vital Therapies CEO Terry Winters cited the following next steps for the company: filing for marketing approval in China, advancing the U.S. clinical program for ELAD, and refining its global strategy.

Vital Therapies was founded in 2003.http://www.airmaxfrance2015.com/

The comments are closed.